The public issue is entirely an offer-for-sale (OFS) of up to 21.7 million shares by the promoters and other shareholders to the tune of around ₹1,800 crore, said bankers. The company operates under the “Blue Jet” brand offering niche products targeted at innovator pharmaceutical companies and multinational generic pharmaceutical companies.
Buying US stocks via Gift City to get easier as Zerodha, others get nod
Buying US stocks could soon become easier for Indian retail investors after Zerodha, Groww, Angel One and Upstox secured regulatory approvals from GIFT City’s IFSCA.